In rare disease, patient advocacy groups often know more about daily life with the condition than anyone else in the room, and they hold the trust of the community a sponsor hopes to enroll. The partnerships that work start early, before the protocol is final, are honest about uncertainty, compensate advocates fairly for their time and expertise, and keep the relationship going after the study ends. Treating advocacy groups as a recruitment channel misses most of their value and can damage trust for years.
Why do advocacy groups matter so much in rare disease?
The patient population is small, geographically scattered and closely connected. Many families know each other. Advocacy groups often run registries, natural history studies and family conferences, and some fund research directly. They understand which outcomes matter to patients, which visits are feasible for families and which burdens will drive people out of a study. A sponsor that ignores that knowledge designs a trial for a patient who doesn't exist.
When should a sponsor engage?
Before the protocol is final, ideally while endpoints, visit schedules and eligibility criteria are still open. Early input can change the choice of outcome measures, reduce unnecessary procedures, identify travel and caregiver burdens and flag eligibility criteria that would exclude much of the community. Engagement that begins at recruitment asks advocates to promote a design they had no chance to shape.
What can advocates contribute?
Protocol feedback on burden, visit frequency, procedures and outcomes that matter to patients.
Informed consent review to make documents clearer and more honest.
Practical insight into travel, caregiving, school and work constraints.
Community communication about the study, in language families trust.
Natural history and registry data that can inform design and feasibility.
Retention support, helping families stay engaged through a long study.
What makes the partnership honest?
Be clear about what the study can and cannot offer. Avoid language that implies benefit before it is shown. Explain randomization and placebo plainly. Share what you can about timelines and setbacks, and say so when you can't share something. Advocacy groups have long memories, and a sponsor that overpromises will find the next study much harder to enroll.
How should sponsors handle compensation and independence?
Pay advocates fairly for their time and expertise, using written agreements, as you would any consultant. Respect the group's independence: they represent patients, not your company. Be transparent about funding relationships, and avoid any arrangement that could look like paying for enrollment. Clear boundaries protect both the group's credibility and yours.
What happens after the study?
Share results with the community in plain language, whether the study succeeded or not. Thank participants and families. Discuss what comes next, including any plans for post-trial access. Keep the relationship going between studies. In a small community, how a sponsor behaves after a disappointing result is remembered at least as well as how it behaved at launch.
How should small sponsors get started?
Map the advocacy groups in your disease area and understand their priorities, histories and relationships with other sponsors. Approach them with curiosity rather than a pitch. Start with a listening conversation about what families need. Then build a plan for engagement across the program, owned by someone senior enough to make commitments and keep them.
Keep reading: Representative Enrollment Is an Operational Design Problem
